ライフサイエンスコーパス: pyridostigmine

1 with a bimolecular rate constant similar to pyridostigmine.

2 butamol to the anticholinesterase medication pyridostigmine.

3 After administration of pyridostigmine, 1 hour before exercise, the GH levels of

4 nts with POTS underwent acute drug trials of pyridostigmine 30 mg orally and placebo, on separate mor

5 1 U/Kg i.v.), clonidine (0.25 mg orally), or pyridostigmine (60 mg orally) were measured in healthy y

6 tigated whether cholinergic stimulation with pyridostigmine, a cholinesterase inhibitor, modulates he

7 nts, galantamine was far more effective than pyridostigmine, a peripherally acting AChE inhibitor, an

8 dostigmine was observed in mice treated with pyridostigmine alone (P < 0.001).

9 Pyridostigmine alone did not stimulate GH secretion in F

10 Pyridostigmine alone reduced postsynaptic areas (P < 0.0

11 Typical myasthenic features such as pyridostigmine and 3, 4- diaminopyridine responsiveness,

12 Combination therapy with pyridostigmine and salbutamol counteracted this decline

13 aried: few showed long-term improvement with pyridostigmine and some even deteriorated with treatment

14 itive AchR Ab should be informed that taking pyridostigmine and/or immunosuppressive agents as well a

15 ith a scale of advanced adverse effects from pyridostigmine bromide (chi2 for trend, P<.001), was gre

16 as performed, except all subjects were given pyridostigmine bromide (Mestinon; 30 mg orally) 1 hour b

17 star rats (n = 15) were provided orally with pyridostigmine bromide (PB) 1.3 mg/kg/day, permethrin (P

18 ned exposure to a nerve gas prophylaxis drug pyridostigmine bromide (PB) and pesticides DEET and perm

19 Additionally, prophylaxis with pyridostigmine bromide (PB) caused DFP-treated animals t

20 Exposure to the antinerve gas drug pyridostigmine bromide (PB) is linked to the development

21 e reversible acetylcholinesterase inhibitor, pyridostigmine bromide (PB), and war-related stress have

22 holinesterase inhibitors (AChEis), including pyridostigmine bromide (PB), pesticides, and nerve agent

23 ing acetylcholinesterase inhibitors, such as pyridostigmine bromide (PYR), aiming to increase parasym

24 GWI was most strongly associated with using pyridostigmine bromide pills [odds ratio (OR) = 3.5; 95%

25 methrin (PER) and the nerve gas prophylactic pyridostigmine-bromide (PB).

26 ive but worsens supine hypertension, whereas pyridostigmine can improve OH slightly but significantly

27 .001) and with advanced adverse effects from pyridostigmine (chi2 for trend, P<.001).

28 Pyridostigmine did not increase the cortisol response to

29 In summary, cholinergic stimulation by pyridostigmine enhances the parasympathetic tone and ind

30 ssive agents (HR 0.42, 95% CI 0.19-0.97) and pyridostigmine (HR 0.37, 95% CI 0.14-0.93).

31 mice, the cholinergic ACh esterase inhibitor pyridostigmine increases ACh levels and bone mass appare

32 Because pyridostigmine is known to reduce somatostatin tone, it

33 e following combination therapy, compared to pyridostigmine monotherapy.

34 butamol and ephedrine alone or combined with pyridostigmine or 3,4-DAP is increasingly being reported

35 Suspect causal agents include the chemicals pyridostigmine (PB), permetrim (PM) and N,N-diethyl-m-to

36 y reported that cholinergic stimulation with pyridostigmine (PY) induces anti-inflammatory cell recru

37 There is evidence that pyridostigmine (PYD) improves the acute response of GH t

38 AH, and the potential therapeutic effects of pyridostigmine (PYR), an oral drug stimulating the paras

39 s have a reduced GH response to exercise, 2) pyridostigmine reverses this impaired response, and 3) d

40 Pyridostigmine significantly decreased the standing hear

41 The pyridophens consist of the basic pyridostigmine skeleton combined with the 2,2-diphenylpr

42 ate was significantly lower at 2 hours after pyridostigmine than after placebo (100+/-16 versus 111+/

43 er study drug was significantly greater with pyridostigmine than placebo (-10.4+/-14.0 AU versus 0.6+

44 In a 1-month trial of oral pyridostigmine therapy, the patient's GI symptoms improv

45 randomly allocated to remain untreated or to pyridostigmine treatment (40 mg/kg once a day by gavage)

46 Pyridostigmine treatment increased the parasympathetic t

47 Pyridostigmine was continued at a low dose, and was supp

48 uability, a gradual decline in the effect of pyridostigmine was observed in mice treated with pyridos

49 s exposure and advanced adverse effects from pyridostigmine were synergistic (Rothman S, 5.3; 95% CI,